Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Cash from Financing Activities (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Cash from Financing Activities for 16 consecutive years, with -$5.8 million as the latest value for Q3 2025.

  • Quarterly Cash from Financing Activities fell 208.6% to -$5.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$6.9 million through Sep 2025, down 139.89% year-over-year, with the annual reading at $16.1 million for FY2024, 18.37% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was -$5.8 million at Xtant Medical Holdings, down from $662000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $18.1 million in Q1 2021, with the low at -$5.8 million in Q3 2025.
  • Average Cash from Financing Activities over 5 years is $3.0 million, with a median of $662000.0 recorded in 2025.
  • Peak annual rise in Cash from Financing Activities hit 53311.76% in 2021, while the deepest fall reached 1515.0% in 2021.
  • Over 5 years, Cash from Financing Activities stood at -$55000.0 in 2021, then soared by 10307.27% to $5.6 million in 2022, then tumbled by 94.21% to $325000.0 in 2023, then plummeted by 362.77% to -$854000.0 in 2024, then tumbled by 575.76% to -$5.8 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$5.8 million, $662000.0, and -$919000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.